Clinical Roundup Phase III Keytruda + Lenvima trial meets PFS, OS endpoints in endometrial cancer following platinum chemo March 26, 2021Vol.47 No.12
Clinical Roundup Phase III trial of Tecentriq in NSCLC meets DFS primary endpoint March 26, 2021Vol.47 No.12
Clinical Roundup Phase II/III trial meets PFS primary endpoint in previously untreated metastatic or unresectable melanoma March 26, 2021Vol.47 No.12
Clinical Roundup Chronic complications from immunotherapies affect 43% of melanoma patients March 26, 2021Vol.47 No.12
Clinical Roundup SignalChem, Merck to evaluate SLC-391 + Keytruda in phase II study of advanced NSCLC March 26, 2021Vol.47 No.12
Drugs & Targets Keytruda receives FDA approval for esophageal or GEJ carcinoma March 26, 2021Vol.47 No.12
Drugs & Targets Evotec, Takeda collaborate on strategic RNA targeting drug discovery and development March 26, 2021Vol.47 No.12
